Business
Jazz Pharmaceuticals to Present Data Showcasing Clinical Advancements Across Oncology Portfolio at 2022 ASCO and EHA Meetings
Key data includes ASCO oral presentation of data from the Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 trial in Acute
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Key data includes ASCO oral presentation of data from the Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 trial in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma\nDUBLIN, May 12, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present seven abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 – June 7, 2022, and eight abstracts at the 27th Annual Congress of the European Hematology Association (EHA) from June 9 –12, 2022. Research findings to be presented include data on Rylaze/JZP458, Zepzelca® (lurbinectedin), Defitelio® (defibrotide sodium) and Vyxeos®/Vyxeos® Liposomal (daunorubicin and cytarabine), also known as JZP351.\n\"As part of Jazz's commitment to explore potential new applications of our oncology medicines to address critical needs, we continue to advance programs that could impact difficult-to-treat therapeutic areas,\" said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. \"Our growing, early-stage pipeline, combined with ongoing Jazz-sponsored and partner research across our portfolio, is making significant progress when it comes to addressing unmet patient needs in cancers that have historically lacked scientific advancements.\"\nHighlights from Jazz and its investigational sponsors at the congresses feature data for our medicines across a range of solid tumors and hematological malignancies, including:\nAn oral presentation at ASCO featuring results from Cohort 1 of a Phase 2/3 trial conducted with the Children's Oncology Group, evaluating the efficacy and safety of Rylaze administered intramuscularly (IM) on a Monday/Wednesday/Friday dosing schedule, for patients living with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).Two poster presentations for JZP351 including preliminary results from Arm B (JZP351 in combination with midostaurin) from the Phase 1b V-FAST trial in adults with previously untreated FLT3-mutated acute myeloid leukemia (AML) and data from the Phase 1b trial evaluating lower-intensity JZP351 + venetoclax in adults with newly diagnosed AML who are unfit for intensive chemotherapy. These data will be presented at both ASCO and EHA.Four poster presentations at ASCO evalua...